US/UK/Canada

Share

Contacts

  • EQT
    http://www.eqtgroup.com

    • Quotes

    EQT Mid Market is seeking to partner with inspiring founders and strong management teams who have a clear vision for their business. We are deeply impressed by the entrepreneurial spirit with which Josef Wildgruber, Uwe Behr and their team have built a true German Mittelstands-Champion over the last years. Very rarely do we find businesses of this size that operate as a truly global platform like BBS Automation. EQT Mid Market is delighted to partner with the co-founders of BBS Automation and their team to further develop this key enabler of Industry 4.0 production systems
    Andreas Fischer, Partner at EQT Partners and Investment Advisor to EQT Mid Market
    Pick a time period -
    Tags ( Active)

    EQT Private Equity to sell Schülke, a sustainability leader in infection prevention and treatment for the healthcare industry

    · EQT Private Equity to sell Schülke to the ATHOS Consortium, having acquired the Company in a carve-out from Air Liquide in July 2020. The Company has delivered double digit annual revenue growth and almost doubled EBITDA in its core healthcare business over this time  · Under EQT Private Equity’s ownership, Schülke has been repositioned to focus entirely on the healthcare and life science market, while expanding into new geographies and sales channels through five add-on acquisitions   · The Company has also established itself as a sustainability leader, for example by launching a

    EQT Future and ATHOS, alongside other co-investors, invest in SHL Medical, a world-leading provider of advanced drug delivery solutions

    · SHL Medical is a pioneer in medical autoinjectors, which allow patients to safely self-administer medications at home while reducing the burden on healthcare systems · EQT first partnered with SHL Medical in January 2020 through its EQT VIII fund. Having outperformed its business plan since, SHL Medical formulated an ambitious growth strategy until 2030, for which EQT Future, ATHOS and other co-investors will serve as partners · The consortium will support SHL Medical in its next phase of growth, expanding its production footprint to the United States and Europe, while further

    EQT Private Equity to sell Facile.it, Italy’s largest online price comparison platform, to Silver Lake

    · EQT Private Equity and Oakley to sell Facile.it, Italy’s leading online destination for consumers to compare prices and save money on key areas of household spending, to Silver Lake  · Under EQT Private Equity’s tenure, Facile.it has continued to pioneer the Online Price Comparison market in Italy and further established its position as clear leader across multiple verticals, strengthening its brand, technology capabilities, and omnichannel presence  · Today, Facile.it reaches a base of over four million unique monthly users via an end-to-end seamless experience across its website,

    EQT Private Equity and TA to welcome Hg as a significant minority partner in IFS and WorkWave at a USD 10bn valuation

    · EQT VIII to sell a large part of its stake in cloud software vendors IFS and WorkWave to Hg, in a transaction valuing the Companies at USD 10bn. EQT Private Equity to remain majority shareholder alongside Hg, TA and the management teams · Since the acquisition by EQT VIII and EQT IX, IFS has grown Cash EBITDA by 51 percent p.a. and established a global leadership position within cloud software for companies which want to differentiate on service · Since separating WorkWave from IFS in 2021, WorkWave has more than tripled revenues by combining a compelling organic growth strategy

    EQT Private Equity to sell Igenomix to Vitrolife for an enterprise value of EUR 1.25 billion

    · Igenomix is a global leader in molecular genetic diagnostics for reproductive medicine and rare diseases - assisting approximately 90,000 patients per year through a diversified portfolio of in vitro fertilization (IVF) and rare diseases genetic testing services · The combination of Igenomix and Vitrolife will create a global leader in reproductive health by combining the knowledge, product portfolios and market presence of two leading companies within IVF medical devices and reproductive genetic testing services  · As part of the transaction, EQT Private Equity will become a

    WorkWave launches as standalone portfolio company following separation from IFS and announces transformational add-ons

    · Previously part of IFS, WorkWave provides software solutions for field service management serving small-to-medium sized businesses with a particular stronghold in the US pest control industry · WorkWave announces the completion of two transformational add-on acquisitions in the US, Real Green and Slingshot, to further strengthen its leadership position in asset-light field service management software · EQT and TA Associates will leverage their strong sector experience, global platforms and extensive advisory networks to support WorkWave’s accelerated growth agenda as a standalone

    EQT Private Equity to sell Aldevron to Danaher Corporation for enterprise value of USD 9.6 billion

    · Aldevron is a leader in manufacturing high-quality plasmid DNA, mRNA and recombinant proteins · Aldevron’s products empower biotech companies to achieve scientific and medical breakthroughs · During EQT’s ownership, Aldevron has experienced strong organic growth and made significant investments to position itself for further expansion EQT is pleased to announce that the EQT VIII fund (“EQT Private Equity”) has agreed to sell Aldevron to Danaher Corporation for an enterprise value of USD 9.6 billion. EQT Private Equity acquired a majority interest in Aldevron in 2019,

    schülke sells its Personal Care Business and completes strategic repositioning to a pureplay healthcare company in infection prevention solutions

    · EQT Private Equity portfolio company schülke sells its Personal Care Business, a leading developer and supplier of preservatives and multifunctional skin care additives, to the Ashland group  · With the divestment, schülke completes its strategic repositioning to an infection prevention solutions provider fully focused on the healthcare industry, ready to accelerate growth  · schülke is playing an instrumental role in combating the COVID-19 pandemic by ensuring the best possible support and supply of disinfectants to its customers EQT is pleased to announce that EQT Private

    EQT funds to acquire global enterprise software provider IFS and bring in TA Associates as minority partner

    · EQT funds to acquire IFS, the leading global enterprise software provider that enables business to digitalize their core operations, for a transaction value in excess of EUR 3 billion · TA Associates to join as a minority partner and will hold a significant minority stake in IFS · EQT funds and TA Associates to support IFS and the management team with continued investments in the organization and product capabilities, both organically and through add-on acquisitions EQT today announced that the EQT VIII and EQT IX funds (“EQT”), together with global growth private equity firm

    EQT enters exclusive negotiations to acquire schülke – a leading provider of infection prevention solutions

    · EQT enters exclusive negotiations to acquire schülke, a leading provider of hygiene and infection prevention solutions, such as skin and surface disinfection products and wound antisepsis · schülke is a pioneer in the infection prevention industry with 130 years of experience, protecting lives worldwide by providing critical products for global disease prevention · After closing, EQT will support schülke and the management team, led by CEO Christian Last, in their next phase of growth and innovation, and further strengthen schülke’s brand and market position The EQT VIII fund

    EQT invests in SHL Medical, a world-leading provider of drug delivery solutions

    · EQT acquires minority stake in SHL Medical, a world-leading manufacturer of advanced drug delivery systems such as autoinjectors · SHL is a pioneer and technology frontrunner in the self-injection industry, promoting well-being for all by allowing patients to safely self-administer medications at home · EQT will support SHL and the management team in its next phase of growth and innovation by leveraging EQT’s healthcare expertise, local angles and digital capabilities The EQT VIII Fund (“EQT”) today announced that it has entered into an agreement to acquire a minority stake

    EQT to acquire majority interest in Aldevron – the leading global supplier of plasmid DNA used in cell and gene therapies

    · EQT to partner with founder and CEO Michael Chambers, as well as TA Associates, to support Aldevron on its future growth journey · EQT will support Aldevron through investments in additional production capacity, R&D, and growth initiatives and by leveraging EQT’s strong healthcare expertise, global presence, and network of Industrial Advisors New York, NY - July 31, 2019 - The EQT VIII Fund (“EQT” or “EQT VIII”) today announced that it has entered into an agreement to acquire a majority interest in Aldevron (the “Company”). Following the close of the transaction, EQT VIII will own

    Consortium led by EQT and ADIA enters exclusive negotiations to acquire skincare company Nestlé Skin Health

    · EQT and a wholly owned subsidiary of the Abu Dhabi Investment Authority (“ADIA”) have partnered with a wholly owned subsidiary of the Public Sector Pension Investment Board (“PSP Investments”) and other renowned institutional investors · The consortium has entered into exclusive negotiations to acquire Nestlé Skin Health, a leading global skincare company · The new owners plan to support Nestlé Skin Health in its next period of growth and innovation by leveraging EQT’s strong healthcare expertise, local angles and industrial network A consortium comprising EQT VIII fund (“EQT”

    EQT acquires Dellner Couplers, a global leader in train connection systems for passenger rail

    · EQT to acquire Dellner Couplers, a global niche market leader in couplers, gangways and adjacent products for passenger rail rolling stock · EQT will support Dellner and the management team with further investments in R&D and innovation initiatives, and accelerate global growth by leveraging EQT’s strong industrial expertise and network of Industrial Advisors · Dellner Couplers contributes to society by developing products that promote safe and sustainable public rail transportation The EQT VIII fund (“EQT” or “EQT VIII”) has entered into an agreement to acquire Dellner

    EQT acquires Igenomix, a global leader in women’s health and reproductive genetic services

    · EQT to acquire Igenomix, one of the world’s leading biotechnology companies and a global leader in women’s health and reproductive genetic services for IVF (In Vitro Fertilization) clinics · Igenomix supports approximately 90,000 couples per year in their reproductive journey · EQT will support Igenomix’s continued international growth journey by leveraging EQT’s strong healthcare expertise, global platform and network of Industrial Advisors The EQT VIII fund (“EQT” or “EQT VIII”) has entered into an agreement to acquire Igenomix (“the Company”) from Charme Capital,

    Karo Intressenter AB publishes supplement to offer document regarding its public cash offer to the shareholders in Karo Pharma Aktiebolag

    On 29 October 2018, EQT VIII[1]  (“EQT VIII”), through Karo Intressenter AB[2]  (“Karo Intressenter”), announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (”Karo Pharma”) to acquire all outstanding shares[3]  in Karo Pharma (the ”Offer”). On 12 November 2018, an offer document regarding the Offer was made public. On 2 January 2019, it was announced that Karo Intressenter had decided to increase the price in the Offer to 38.00 in cash per share. As a consequence thereof, Karo Intressenter has prepared a supplement to the

    Karo Intressenter AB increases the offer price in its public cash offer to the shareholders in Karo Pharma Aktiebolag and extends the acceptance period

    On 29 October 2018, EQT VIII[1]  (“EQT VIII”), through Karo Intressenter AB[2]  (“Karo Intressenter”), announced a public cash offer to the shareholders in Karo Pharma Aktiebolag (”Karo Pharma”) to acquire all outstanding shares[3]  in Karo Pharma (the ”Offer”). Karo Intressenter has decided to increase the price in the Offer from SEK 36.90 in cash per share to SEK 38.00 in cash per share. Karo Intressenter further extends the acceptance period up to and including 17:00 (CET) on 17

    EQT acquires Cast & Crew – a leading provider of software and services to the entertainment industry

    · EQT VIII acquires Cast & Crew, a leading provider of software and services to the entertainment industry, covering payroll & human resources, accounting & financial management and workflow & productivity · Cast & Crew’s solutions simplify and automate complex processes for companies and productions in the film, television, digital streaming, commercial and live events markets · EQT will support Cast & Crew’s impressive growth trajectory by leveraging its operational and financial resources, including deep sector expertise within TMT and Services and its global network of

    EQT acquires Saxo Payments Banking Circle

    · EQT VIII and EQT Ventures, in partnership with Saxo Payments Banking Circle’s founders and other co-investors, to acquire Saxo Payments Banking Circle · Saxo Payments Banking Circle’s unique banking platform enables cross-border payments with reduced complexity, time and cost · EQT to support Saxo Payments Banking Circle’s continued growth by leveraging the entire EQT platform, including around 25 years of experience in future-proofing companies as well as accelerating hyper-growth businesses, deep TMT expertise, and a global industrial network The EQT VIII fund (“EQT VIII”)

    EQT to acquire leading open source software provider SUSE

    · EQT VIII to acquire SUSE, a leading global provider of open source infrastructure software for enterprises · EQT VIII is partnering with CEO Nils Brauckmann and his team to support SUSE’s next period of growth and innovation, and to strengthen its position as leading open source player both organically and through add-on acquisitions · SUSE to further build its brand and unique corporate culture as a stand-alone business The EQT VIII fund (“EQT” or “EQT VIII”) has agreed to acquire SUSE, a leading global provider of open source infrastructure software for large enterprises,

    EQT granted exclusivity to acquire Azelis, a global distributor of specialty chemicals and food ingredients

    · EQT VIII, with PSP Investments as co-investor, is in exclusive discussions to acquire Azelis, a leading distributor of specialty chemicals and food ingredients with a global presence in more than 40 countries · Azelis provides a diverse range of products and innovative services to more than 43,000 customers and 2,000 principals · EQT VIII to support Azelis’ continued growth by leveraging EQT’s experience with buy-and-build strategies, digital capabilities and global network of industrial advisors The EQT VIII fund (“EQT” or “EQT VIII”), in partnership with the Public Sector

    EQT acquires Italian online price comparison platform Facile.it

    · EQT VIII to acquire Facile.it, Italy’s leading online price comparison platform · Facile.it helps approximately 20 million users in Italy to save money within motor insurance, energy, telecoms and personal financial products · EQT VIII will support Facile.it’s continued growth journey by leveraging EQT’s strong TMT expertise, local angles and industrial network The EQT VIII fund (“EQT” or “EQT VIII”) has entered into an agreement to acquire Facile.it (“Facile” or “the company”) from Oakley Capital and other minority owners. Oakley Capital will re-invest into the company while

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media